A nano-ultrasound contrast agent targeting CD147 and a preparation method and application thereof
By conjugating gas vesicles with CD147 nanobodies, the problems of large particle size, poor targeting, and complex preparation of existing ultrasound contrast agents are solved, realizing efficient targeted imaging and integrated diagnosis and treatment of tumor tissues, which has broad application prospects.
CN120550147BActive Publication Date: 2026-07-10BEIJING HOSPITAL
3 Cites 0 Cited by
Patent Information
- Application Number
- CN202510727601.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-03
- Publication Date
- 2026-07-10
- Estimated Expiration
- 2045-06-03
AI Technical Summary
Technical Problem
Existing ultrasound contrast agents are difficult to achieve efficient targeted imaging and diagnosis of tumor tissues due to their large particle size, poor targeting, complex preparation, and safety risks.
Method used
By conjugating microbial-derived gas vesicles with CD147 nanobodies and linking them with maleimide polyethylene glycol active esters, a highly targeted and safe nano-ultrasound contrast agent is formed, which, combined with anti-tumor drugs, achieves integrated diagnosis and treatment.
Benefits of technology
It significantly improves imaging contrast and targeting, reduces preparation costs, enhances safety, and has drug delivery capabilities, making it suitable for the precise diagnosis and treatment of various tumors.
✦ Generated by Eureka AI based on patent content.
Abstract
This invention provides a CD147-targeting nano-ultrasound contrast agent, its preparation method, and its application. The contrast agent comprises: microbial-derived gas vesicles and CD147 nanoantibodies linked to the surface of the gas vesicles via a coupling agent. The hollow nanostructure of the gas vesicles in this invention endows the contrast agent with highly efficient acoustic reflection capabilities, significantly improving the ultrasound signal intensity. The CD147 nanoantibodies possess high affinity and high specificity, enabling precise recognition of the CD147 antigen on the surface of tumor cells. This invention uses biosynthesized gas vesicles instead of traditional chemically synthesized gas microbubbles, combined with a simple and efficient coupling process, significantly reducing preparation difficulty and equipment dependence. The contrast agent of this invention overcomes the shortcomings of existing technologies in imaging performance, targeting, preparation process, safety, and multifunctional diagnostic and therapeutic capabilities, providing a novel technical pathway for precision diagnosis and treatment of tumors.
Need to check novelty before this filing date? Find Prior Art